How do you really feel after taking Upatinib/Refor for two years? Is it really effective?

Upadacitinib is a selective JAK1 inhibitor, mainly used for the treatment of moderate to severe rheumatoid arthritis (RA) and other immune-related diseases. For many patients, the real experience of long-term use for two years can be evaluated from multiple dimensions such as efficacy, improvement in quality of life, and management of side effects. Clinical and overseas patient feedback shows that upadatinib is effective in relieving joint pain, reducing joint swelling, improving morning stiffness, and improving mobility. Patients can usually observe relief from pain and inflammation within a few weeks of taking the medication. After one to two years of continuous medication, most people's joint function is significantly improved, and their daily life and work abilities are improved.

Patients who have been using it for two years generally report that upadatinib remains stable in controlling disease activity. Compared with traditional disease-modifying antirheumatic drugs (DMARDs), upadatinib has a faster onset of action and longer-lasting effects. Some patients need to communicate closely with their doctor to adjust the dosage in the first few months after starting treatment to ensure that the drug has the best effect while minimizing side effects. By regularly reviewing blood routine, liver and kidney function, and blood lipid levels, doctors can detect potential risks in time and optimize treatment plans.

From a mechanism perspective, upadatinib selectively inhibits the JAK1 signaling pathway and reduces the expression of pro-inflammatory cytokines, which not only alleviates joint inflammation, but also reduces systemic symptoms such as fatigue, fever and muscle pain. Long-term patient feedback shows that it significantly improves pain and morning stiffness, thereby significantly improving quality of life and activity tolerance. It is worth noting that the effect of upadatinib varies depending on individual differences, and some patients may need to be combined with other drugs or the treatment plan may need to be adjusted to achieve the best effect.

Reference materials:https://www.rinvoq.com/